ES2144527T3 - Metodo para el tratamiento de disfunciones en la reproduccion. - Google Patents

Metodo para el tratamiento de disfunciones en la reproduccion.

Info

Publication number
ES2144527T3
ES2144527T3 ES94926472T ES94926472T ES2144527T3 ES 2144527 T3 ES2144527 T3 ES 2144527T3 ES 94926472 T ES94926472 T ES 94926472T ES 94926472 T ES94926472 T ES 94926472T ES 2144527 T3 ES2144527 T3 ES 2144527T3
Authority
ES
Spain
Prior art keywords
dysfunctions
reproduction
treatment
insulin
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926472T
Other languages
English (en)
Inventor
Christopher A Maack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2144527T3 publication Critical patent/ES2144527T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTE ES UN METODO PARA EL TRATAMIENTO DE LOS TRASTORNOS ASOCIADOS A LA REPRODUCCION EN LOS QUE SE PRODUCE UNA INSUFICIENCIA DE LA MADURACION DE LOS GAMETOS EN LOS SUJETOS, MEDIANTE LA ADMINISTRACION DE UN COMPUESTO QUE CONTIENE UN COMPLEJO CON UN FACTOR DE CRECIMIENTO SIMILAR AL DE LA INSULINA (IGF) Y UNA PROTEINA DE UNION 3 DEL FACTOR DE CRECIMIENTO SIMILAR AL DE LA INSULINA (IGFBP-3).
ES94926472T 1993-08-03 1994-08-02 Metodo para el tratamiento de disfunciones en la reproduccion. Expired - Lifetime ES2144527T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10125593A 1993-08-03 1993-08-03

Publications (1)

Publication Number Publication Date
ES2144527T3 true ES2144527T3 (es) 2000-06-16

Family

ID=22283716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94926472T Expired - Lifetime ES2144527T3 (es) 1993-08-03 1994-08-02 Metodo para el tratamiento de disfunciones en la reproduccion.

Country Status (11)

Country Link
EP (1) EP0723453B1 (es)
JP (1) JPH09503753A (es)
AT (1) ATE190499T1 (es)
AU (1) AU674449B2 (es)
CA (1) CA2168790A1 (es)
DE (1) DE69423506T2 (es)
DK (1) DK0723453T3 (es)
ES (1) ES2144527T3 (es)
GR (1) GR3033523T3 (es)
PT (1) PT723453E (es)
WO (1) WO1995003817A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
CA2422625A1 (en) 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US6887851B2 (en) 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
ATE382364T1 (de) 2001-09-18 2008-01-15 Bioexpertise Llc Von igf-bindungsprotein stammendes peptid
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
JP2005518823A (ja) 2002-03-08 2005-06-30 マクギル・ユニバーシテイ 未成熟ヒト卵母細胞の体外成熟
ES2341270T3 (es) 2004-12-24 2010-06-17 Insmed, Inc. Complejos rhigf-i/rhigfbp-3 purificados y procedimientos de fabricacion de los mismos.
US20160237402A1 (en) * 2013-10-07 2016-08-18 Northeastern University Methods and Compositions for Ex Vivo Generation of Developmentally Competent Eggs from Germ Line Cells Using Autologous Cell Systems
CN107073036A (zh) 2014-03-27 2017-08-18 东北大学 用于卵巢卵泡生长和成熟的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur

Also Published As

Publication number Publication date
EP0723453B1 (en) 2000-03-15
PT723453E (pt) 2000-07-31
CA2168790A1 (en) 1995-02-09
WO1995003817A1 (en) 1995-02-09
GR3033523T3 (en) 2000-09-29
DE69423506D1 (de) 2000-04-20
EP0723453A1 (en) 1996-07-31
EP0723453A4 (en) 1997-01-29
AU7629794A (en) 1995-02-28
DE69423506T2 (de) 2000-09-21
JPH09503753A (ja) 1997-04-15
AU674449B2 (en) 1996-12-19
DK0723453T3 (da) 2000-06-05
ATE190499T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
ES2144527T3 (es) Metodo para el tratamiento de disfunciones en la reproduccion.
ES2067720T3 (es) Composicion y metodo para el tratamiento de la osteoporosis en mamiferos.
ATE156018T1 (de) Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose
FI93460B (fi) Menetelmä uusien insuliinijohdannaisten valmistamiseksi
BG101392A (en) Method of treating diabetes mellitus using kgf
EP0726911A4 (en) TREATMENT OF IMMUNOLOGICAL AND HEMATOLOGICAL DISORDERS USING IGFBP ALONE OR ASSOCIATED WITH IGF
ES2174852T3 (es) Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
ATE121296T1 (de) Igf-i zur behandlung von nebeneffekten der steroidtherapie.
GR3020869T3 (en) Immediate-effect flurbiprofen-containing medicament and its use.
SE9303068D0 (sv) New use
SE9303784D0 (sv) Igf
EP0092386A3 (en) Hydantoin therapeutic agents
DE3479477D1 (en) A pharmaceutical composition for use in treating neurological disease or aging
DE69006032T2 (de) Verfahren zur behandlung von unfruchtbarkeit oder verminderter fruchtbarkeit bei erwachsenen männern und die verwendung von präparaten in diesem verfahren.
UA7191A (uk) Спосіб лікування запально-гнійних процесів в легенях
EP0147194A3 (en) Method and compositions for treating cerebral ischemia
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 723453

Country of ref document: ES